Turn Therapeutics Q3 net loss more than triples to $6.23 million
TTRX•Turn Therapeutics’ third-quarter 2026 net loss more than tripled year over year to $6.23 million. It had $10.36 million in cash and equivalents at September 30 and expects funding to last into the third quarter of 2027.
1. Quarterly results and outlook
Turn Therapeutics reported a third-quarter 2026 net loss of $6.23 million, more than triple the year-earlier loss. Research and development spending more than tripled to $605,197, while general and administrative expenses fell 21% to $1.38 million. The company had $10.36 million in cash and equivalents at September 30 and expects operations to remain funded into the third quarter of 2027.
2. Trial timelines
Topline results from the ongoing Phase 2b atopic dermatitis trial of GX-03 are expected in the first quarter of 2027. Enrollment in the planned Phase 2a hidradenitis suppurativa trial is scheduled to begin in the first quarter of 2027, ahead of the second-quarter target.
